Guest guest Posted July 23, 2003 Report Share Posted July 23, 2003 TENOFOVIR AND D4T GO HEAD TO HEAD Cal Cohen, M.D., reports on the most recent results from the pivotal trial of tenofovir (Viread) + 3TC (lamviudine, Epivir) + efavirenz vs. d4T (stavudine, Zerit) + 3TC + efavirenz. He writes: "The tenofovir arm has been influential in establishing an attractive outcome not just for response rates, but for safety as well, since the tenofovir arm had few side effects, and a notably low rate of lipodystrophy, as seen at week 96." http://www.thebody.com/confs/ias2003/cohen3.html?m5 AOL users: click here Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.